Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury.

Whetstone WD, Walker B, Trivedi A, Lee S, Noble-Haeusslein LJ, Hsu JC.

PLoS One. 2017 Jan 25;12(1):e0170512. doi: 10.1371/journal.pone.0170512. eCollection 2017.

2.

2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Griffin JH, Mosnier LO, Fernández JA, Zlokovic BV.

Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2143-2151. Epub 2016 Oct 6. Review.

3.

Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.

Griffin JH, Fernández JA, Lyden PD, Zlokovic BV.

Thromb Res. 2016 May;141 Suppl 2:S62-4. doi: 10.1016/S0049-3848(16)30368-1. Review.

4.

Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke.

Amar AP, Griffin JH, Zlokovic BV.

Front Cell Neurosci. 2015 Sep 2;9:344. doi: 10.3389/fncel.2015.00344. eCollection 2015. Review.

5.

Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Mosnier LO, Zlokovic BV, Griffin JH.

Thromb Haemost. 2014 Nov;112(5):883-92. doi: 10.1160/TH14-05-0448. Epub 2014 Sep 18. Review.

6.

Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.

Lyden P, Levy H, Weymer S, Pryor K, Kramer W, Griffin JH, Davis TP, Zlokovic B.

Curr Pharm Des. 2013;19(42):7479-85.

7.

Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.

Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV.

Stroke. 2013 Dec;44(12):3529-36. doi: 10.1161/STROKEAHA.113.003350. Epub 2013 Oct 24.

8.

An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.

Guo H, Zhao Z, Yang Q, Wang M, Bell RD, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV.

J Neurosci. 2013 Apr 3;33(14):6181-90. doi: 10.1523/JNEUROSCI.4491-12.2013.

9.

Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.

Wang Y, Sinha RK, Mosnier LO, Griffin JH, Zlokovic BV.

Blood Cells Mol Dis. 2013 Aug;51(2):104-8. doi: 10.1016/j.bcmd.2013.02.009. Epub 2013 Mar 29.

10.

Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.

Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV.

Brain Res. 2013 Apr 24;1507:97-104. doi: 10.1016/j.brainres.2013.02.023. Epub 2013 Feb 21.

11.

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study.

Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, Nakagawa T.

Thromb J. 2013 Feb 18;11(1):3. doi: 10.1186/1477-9560-11-3.

12.

An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV.

Stroke. 2012 Sep;43(9):2444-9. doi: 10.1161/STROKEAHA.112.658997. Epub 2012 Jul 17.

13.

The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.

Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU, Lawrence DA.

J Thromb Haemost. 2011 Jun;9(6):1174-82. doi: 10.1111/j.1538-7836.2011.04269.x.

14.

Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.

Berny-Lang MA, Hurst S, Tucker EI, Pelc LA, Wang RK, Hurn PD, Di Cera E, McCarty OJ, Gruber A.

Stroke. 2011 Jun;42(6):1736-41. doi: 10.1161/STROKEAHA.110.603811. Epub 2011 Apr 21.

15.

Cytoprotective protein C pathways and implications for stroke and neurological disorders.

Zlokovic BV, Griffin JH.

Trends Neurosci. 2011 Apr;34(4):198-209. doi: 10.1016/j.tins.2011.01.005. Epub 2011 Feb 25. Review.

16.

Fingolimod provides long-term protection in rodent models of cerebral ischemia.

Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V, Liao JK, Lo EH, Waeber C.

Ann Neurol. 2011 Jan;69(1):119-29. doi: 10.1002/ana.22186. Epub 2010 Nov 12.

17.

Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury.

Shlosberg D, Benifla M, Kaufer D, Friedman A.

Nat Rev Neurol. 2010 Jul;6(7):393-403. doi: 10.1038/nrneurol.2010.74. Epub 2010 Jun 15. Review.

18.

Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact.

Walker CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV.

Brain Res. 2010 Aug 6;1347:125-31. doi: 10.1016/j.brainres.2010.05.075. Epub 2010 Jun 1.

19.

Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.

Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández JA, Chow N, Griffin JH, Zlokovic BV.

Eur J Neurosci. 2009 Mar;29(6):1119-30. doi: 10.1111/j.1460-9568.2009.06664.x.

20.

Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.

Guo H, Wang Y, Singh I, Liu D, Fernández JA, Griffin JH, Chow N, Zlokovic BV.

J Neurochem. 2009 Apr;109(1):116-24. doi: 10.1111/j.1471-4159.2009.05921.x. Epub 2009 Jan 23.

Supplemental Content

Support Center